Results of the GLAGOV Trial: Global Assessment of Plaque Regression With a PCSK9 Antibody as Measured by Intravascular Ultrasound

Login

Password

Forgot your password?

Join VuMedi

Select specialty

First name

Last name

Choose Password

About Us
Careers
Partner with us
F.A.Q
Contact us
Terms & conditions
Privacy policy

Playback speed

10 seconds

Results of the GLAGOV Trial: Global Assessment of Plaque Regression With a PCSK9 Antibody as Measured by Intravascular Ultrasound

By Cleveland Clinic Heart, Vascular and Thoracic Institute FEATURING Steven Nissen

1,402 views

January 19, 2017

Dr. Steven Nissen presents the findings and insights from the GLAGOV Trial, an intravascular ultrasound ...
read more ↘ trial looking at the addition of a PCSK9 inhibitor evolocumab in patients treated with statins who have coronary artery disease. Read article at http://jamanetwork.com/journals/jama/fullarticle/2584184
↖ read less

Comments 1